CDK4 and bone metastasis: Among patients with bone metastasis only, Yuan et al. found that ET was preferred as their first-line treatment [30], and further study by Schettini et al. showed that the addition of CDK4/6i to ET had a non-statistically significant benefit (HR = 0.82, P = 0.23) [42].